Valneva Se - Understand $valn stock

$VALN Market Cap: $428.6 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$221.6M

TTM

Gross Margin

38.5%

TTM

Net Earnings

-$7.723M

TTM

Current Assets

$269.2M

Q2 2024

Current Liabilities

$102.5M

Q2 2024

Current Ratio

262.62%

Q2 2024

Total Assets

$466.6M

Q2 2024

Total Liabilities

$300.3M

Q2 2024

Book Value

$166.3M

Q2 2024

Cash

P/E

-55.49

Nov 29, 2024 EST

Free Cash Flow

-$214.9M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Revenue	$153.7M	$361.3M	$348.1M	$110.3M	$126.2M	$113.0M	$105.3M	$94.06M	$78.36M	$36.92M	$30.40M	$3.400M	$10.30M	$4.800M	$3.100M	$3.400M	$900.0K	$2.300M	$3.000M	$1.400M
YoY Change	-57.46%	3.8%	215.52%	-12.58%	11.64%	7.35%	11.94%	20.04%	112.23%	21.45%	794.12%	-66.99%	114.58%	54.84%	-8.82%	277.78%	-60.87%	-23.33%	114.29%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Revenue	$153.7M	$361.3M	$348.1M	$110.3M	$126.2M	$113.0M	$105.3M	$94.06M	$78.36M	$36.92M	$30.40M	$3.400M	$10.30M	$4.800M	$3.100M	$3.400M	$900.0K	$2.300M	$3.000M	$1.400M
Cost Of Revenue	$100.9M	$324.4M	$182.2M	$46.90M	$49.97M	$44.45M	$45.98M	$43.08M	$46.96M	$17.14M	$16.50M	$6.400M	$1.900M	$1.900M	$1.700M	-$500.0K	-$400.0K	-$1.000M	-$900.0K	-$800.0K
Gross Profit	$52.84M	$36.86M	$165.9M	$63.42M	$76.23M	$68.59M	$59.31M	$50.99M	$31.40M	$19.78M	$13.90M	-$3.000M	$8.400M	$3.000M	$1.400M	$3.900M	$1.300M	$3.300M	$3.900M	$2.200M
Gross Profit Margin	34.37%	10.2%	47.65%	57.49%	60.4%	60.68%	56.33%	54.2%	40.07%	53.57%	45.72%	-88.24%	81.55%	62.5%	45.16%	114.71%	144.44%	143.48%	130.0%	157.14%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Selling, General & Admin	$96.55M	$57.58M	$70.76M	$45.17M	$42.28M	$37.84M	$33.42M	$31.20M	$23.63M	$14.40M	$15.00M	$7.300M	$12.70M	$11.80M	$9.300M	$8.100M	$5.400M	$3.900M	$3.400M	$2.500M
YoY Change	67.68%	-18.62%	56.65%	6.85%	11.73%	13.22%	7.14%	32.01%	64.1%	-4.0%	105.48%	-42.52%	7.63%	26.88%	14.81%	50.0%	38.46%	14.71%	36.0%
% of Gross Profit	182.73%	156.21%	42.66%	71.23%	55.46%	55.17%	56.35%	61.19%	75.26%	72.81%	107.91%		151.19%	393.33%	664.29%	207.69%	415.38%	118.18%	87.18%	113.64%
Research & Development	$59.89M	€104.9M	$168.6M	$61.35M	$36.78M	$24.29M	$22.16M	$24.59M	$25.37M	$22.24M	$21.40M	$11.10M
YoY Change	-42.92%	-37.76%	174.77%	66.8%	51.43%	9.64%	-9.89%	-3.07%	14.05%	3.93%	92.88%
% of Gross Profit	113.35%	284.63%	101.64%	96.74%	48.25%	35.42%	37.36%	48.23%	80.79%	112.46%	153.96%
Depreciation & Amortization	$17.58M	$21.04M	$14.28M	$9.799M	$8.532M	$6.828M	$11.14M	$11.27M	$11.44M	$12.36M	$9.060M	$4.780M	$3.320M	$2.720M	$1.530M	$1.330M	$690.0K	$330.0K	$1.520M	$900.0K
YoY Change	-16.41%	47.3%	45.74%	14.85%	24.96%	-38.71%	-1.14%	-1.51%	-7.42%	36.41%	89.54%	43.98%	22.06%	77.78%	15.04%	92.75%	109.09%	-78.29%	68.89%
% of Gross Profit	33.28%	57.07%	8.61%	15.45%	11.19%	9.96%	18.78%	22.1%	36.44%	62.49%	65.18%		39.52%	90.67%	109.29%	34.1%	53.08%	10.0%	38.97%	40.91%
Operating Expenses	$134.9M	€104.9M	$221.5M	$92.13M	$76.95M	$62.32M	$63.27M	$93.43M	$51.36M	$43.53M	$36.10M	$8.600M	$13.40M	$11.40M	$7.600M	$7.100M	$6.100M	$3.600M	$5.300M	$3.200M
YoY Change	28.6%	-52.63%	140.44%	19.73%	23.47%	-1.5%	-32.29%	81.9%	17.99%	20.59%	319.77%	-35.82%	17.54%	50.0%	7.04%	16.39%	69.44%	-32.08%	65.63%
Operating Profit	-$82.09M	-$68.06M	-$55.65M	-$28.71M	-$719.0K	$6.268M	-$3.954M	-$42.44M	-$19.96M	-$23.75M	-$22.20M	-$11.60M	-$5.000M	-$8.400M	-$6.200M	-$3.200M	-$4.800M	-$300.0K	-$1.400M	-$1.000M
YoY Change	20.61%	22.3%	93.83%	3893.05%	-111.47%	-258.52%	-90.68%	112.61%	-15.96%	7.0%	91.38%	132.0%	-40.48%	35.48%	93.75%	-33.33%	1500.0%	-78.57%	40.0%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Interest Expense	-$16.54M	-$31.37M	-$8.281M	-$10.18M	-$59.00K	-$2.909M	-$8.606M	-$6.260M	-$13.64M	-$2.121M	-$2.800M	-$500.0K	$100.0K	-$400.0K	$200.0K	$800.0K	-$200.0K	-$100.0K	-$100.0K	$0.00
YoY Change	-47.27%	278.84%	-18.67%	17157.63%	-97.97%	-66.2%	37.48%	-54.11%	543.19%	-24.25%	460.0%	-600.0%	-125.0%	-300.0%	-75.0%	-500.0%	100.0%	0.0%
% of Operating Profit						-46.41%
Other Income/Expense, Net	-$1.000K	-$264.0K	-$308.0K			-$1.000K		$0.00	$13.18M	$0.00	$100.0K	$500.0K	$0.00	$0.00	$0.00	$0.00	$600.0K	$100.0K	$100.0K	-$300.0K
YoY Change	-99.62%	-14.29%						-100.0%		-100.0%	-80.0%	-56294995342131300.0%	-200.0%	100.0%	0.0%	-100.0%	500.0%	0.0%	-133.33%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Pretax Income	-$98.63M	-$144.8M	-$69.98M	-$65.30M	-$870.0K	$3.351M	-$12.56M	-$48.83M	-$20.39M	-$25.94M	-$23.60M	-$12.90M	-$4.400M	-$9.500M	-$6.100M	-$2.400M	-$4.400M	-$200.0K	-$1.400M	-$1.000M
YoY Change	-31.89%	106.94%	7.16%	7405.98%	-125.96%	-126.68%	-74.28%	139.44%	-21.38%	9.91%	82.95%	193.18%	-53.68%	55.74%	154.17%	-45.45%	2100.0%	-85.71%	40.0%
Income Tax	$2.800M	-$1.536M	$3.446M	-$909.0K	$874.0K	$88.00K	-$1.078M	$356.0K	$224.0K	$334.0K	$300.0K	$100.0K	$0.00	-$1.500M	$0.00	$0.00	-$1.000M	$0.00	-$200.0K	-$300.0K
% Of Pretax Income						2.63%
Net Earnings	-$101.4M	-€143.3M	-$73.43M	-$64.39M	-$1.744M	$3.263M	-$11.48M	-$49.18M	-$20.62M	-$26.27M	-$24.10M	-$14.80M	-$4.400M	-$8.000M	-$6.100M	-$2.400M	-$3.400M	-$200.0K	-$1.200M	-$700.0K
YoY Change	-29.21%	95.14%	14.03%	3592.26%	-153.45%	-128.42%	-76.66%	138.56%	-21.52%	9.01%	62.84%	236.36%	-45.0%	31.15%	154.17%	-29.41%	1600.0%	-83.33%	71.43%
Net Earnings / Revenue	-65.99%	-39.66%	-21.09%	-58.37%	-1.38%	2.89%	-10.91%	-52.29%	-26.31%	-71.16%	-79.28%	-435.29%	-42.72%	-166.67%	-196.77%	-70.59%	-377.78%	-8.7%	-40.0%	-50.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.73	-$1.24	-$752.2K	-$709.5K	-$19.01K	$39.99K	-$148.3K	-$658.8K	-$283.4K	-$426.9K	-$552.8K	-$560.6K	-$167.9K	-$368.7K	-$297.6K	-$117.1K	-$167.5K	-$9.950K	-$59.70K	-$34.83K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Cash & Short-Term Investments	$126.1M	$289.4M	$346.6M	$204.4M	$64.44M	$77.08M	$33.55M	$35.27M	$41.91M	$28.88M	$40.20M	$12.10M	$30.60M	$42.50M	$23.60M	$22.70M	$25.00M	$1.800M	$5.000M	$2.500M
YoY Change	-56.44%	-16.5%	69.59%	217.19%	-16.4%	129.79%	-4.88%	-15.84%	45.13%	-28.17%	232.23%	-60.46%	-28.0%	80.08%	3.96%	-9.2%	1288.89%	-64.0%	100.0%
Cash & Equivalents		$289.4M				-$1.000K		-$1.000K	$0.00	$1.284M	$36.50M	$700.0K	$9.700M	$16.00M	$17.50M	$18.40M	$13.40M
Short-Term Investments				$31.29M	$25.00M	$20.00M	$1.004M	$1.002M	$3.726M	$0.00	$3.700M	$11.20M	$20.60M	$7.800M	$0.00	$4.000M	$11.60M	$1.700M	$3.400M
Other Short-Term Assets	$50.63M	$76.21M	$71.08M	$57.87M	$14.92M	$14.90M	$12.35M	$16.32M	$32.03M	$9.959M	$10.80M	$700.0K	$100.0K	$100.0K	$100.0K	$100.0K
YoY Change	-33.56%	7.22%	22.83%	287.83%	0.13%	20.66%	-24.31%	-49.07%	221.67%	-7.79%	1442.86%	600.0%	0.0%	0.0%	0.0%
Inventory	$44.47M	$35.10M	$124.1M	$26.93M	$25.77M	$22.73M	$19.93M	$22.70M	$26.69M	$7.282M	$4.800M	$900.0K	$1.000M	$600.0K	$400.0K	$300.0K	$200.0K	$200.0K	$200.0K	$200.0K
Prepaid Expenses
Receivables	$41.65M	$23.91M	$44.01M	$19.23M	$24.03M	$11.26M	$17.62M	$16.91M	$15.75M	$6.850M	$7.600M	$1.000M	$900.0K	$500.0K	$700.0K	$1.400M	$600.0K	$1.300M	$100.0K	$200.0K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$300.0K	$1.000M	$3.100M	$5.000M	$4.600M	$2.300M	$2.000M	$1.700M	$1.000M
Total Short-Term Assets	$262.8M	$424.7M	$585.8M	$308.4M	$129.2M	$126.0M	$83.45M	$91.20M	$116.4M	$52.97M	$63.30M	$15.10M	$33.50M	$46.90M	$29.80M	$29.10M	$28.10M	$5.300M	$7.100M	$3.800M
YoY Change	-38.11%	-27.51%	89.94%	138.79%	2.53%	50.96%	-8.5%	-21.64%	119.73%	-16.32%	319.21%	-54.93%	-28.57%	57.38%	2.41%	3.56%	430.19%	-25.35%	86.84%
Property, Plant & Equipment	$156.6M	$154.0M	$173.8M	$78.15M	$69.34M	$38.00M	$38.37M	$39.04M	$42.44M	$41.61M	$45.10M	$12.10M	$13.30M	$13.10M	$8.700M	$5.900M	$5.400M	$5.100M	$4.300M	$900.0K
YoY Change	1.66%	-11.39%	122.42%	12.71%	82.48%	-0.98%	-1.7%	-8.01%	1.99%	-7.74%	272.73%	-9.02%	1.53%	50.57%	47.46%	9.26%	5.88%	18.6%	377.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$0.00	$2.124M	$2.130M	$2.263M	$1.122M				$0.00		$200.0K	$200.0K	$200.0K	$400.0K	$100.0K	$100.0K	$0.00	$0.00	$0.00
YoY Change		-100.0%	-0.28%	-5.88%	101.69%							0.0%	0.0%	-50.0%	300.0%	0.0%
Other Assets	$15.08M	$13.94M	$22.87M	$25.05M	$22.15M	$19.93M	$19.05M	$17.69M	$17.80M	$27.74M	$20.60M	$8.900M	$6.000M	$3.800M	$1.900M	$700.0K	$1.200M	$600.0K	$600.0K	$600.0K
YoY Change	8.22%	-39.06%	-8.7%	13.08%	11.16%	4.58%	7.72%	-0.62%	-35.83%	34.64%	131.46%	48.33%	57.89%	100.0%	171.43%	-41.67%	100.0%	0.0%	0.0%
Total Long-Term Assets	$197.2M	$196.7M	$231.5M	$140.7M	$135.6M	$103.9M	$105.9M	$115.7M	$158.8M	$174.6M	$191.1M	$38.60M	$39.60M	$32.60M	$16.20M	$12.30M	$11.50M	$9.600M	$7.500M	$4.700M
YoY Change	0.28%	-15.05%	64.51%	3.82%	30.43%	-1.85%	-8.46%	-27.15%	-9.02%	-8.66%	395.08%	-2.53%	21.47%	101.23%	31.71%	6.96%	19.79%	28.0%	59.57%
Total Assets	$460.1M	$621.3M	$817.4M	$449.2M	$264.7M	$229.9M	$189.3M	$206.9M	$275.2M	$227.5M	$254.4M	$53.70M	$73.10M	$79.50M	$46.00M	$41.40M	$39.60M	$14.90M	$14.60M	$8.500M
YoY Change
Accounts Payable	$17.56M	$41.49M	$16.04M	$24.90M	$8.868M	$9.175M	$5.258M	$2.554M	$6.325M	$5.192M	$6.500M	$1.900M	$1.400M	$900.0K	$1.000M	$1.000M	$800.0K	$600.0K	$500.0K	$200.0K
YoY Change	-57.67%	158.75%	-35.6%	180.76%	-3.35%	74.5%	105.87%	-59.62%	21.82%	-20.12%	242.11%	35.71%	55.56%	-10.0%	0.0%	25.0%	33.33%	20.0%	150.0%
Accrued Expenses	$42.95M	$15.74M	$69.33M	$24.48M	$18.32M	$12.79M	$11.80M	$12.38M	$11.26M	$11.22M	$10.00M	$1.800M	$1.800M	$1.500M	$1.300M	$900.0K	$600.0K	$600.0K	$600.0K	$300.0K
YoY Change	172.89%	-77.3%	183.23%	33.6%	43.23%	8.42%	-4.68%	9.92%	0.41%	12.15%	455.56%	0.0%	20.0%	15.38%	44.44%	50.0%	0.0%	0.0%	100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$46.96M	$36.99M	$10.24M	$9.684M	$4.307M	$17.53M	$17.40M	$20.96M	$25.69M	$7.117M	$6.400M	$1.600M	$1.500M	$1.300M	$1.000M	$800.0K	$600.0K	$400.0K	$400.0K
YoY Change	26.94%	261.17%	5.76%	124.84%	-75.43%	0.75%	-16.99%	-18.41%	260.92%	11.2%	300.0%	6.67%	15.38%	30.0%	25.0%	33.33%	50.0%	0.0%
Total Short-Term Liabilities	$158.9M	$277.4M	$369.0M	$175.9M	$41.30M	$42.94M	$37.67M	$38.89M	$46.36M	$26.39M	$28.10M	$9.800M	$13.30M	$12.90M	$7.000M	$5.300M	$3.900M	$3.300M	$3.500M	$1.500M
YoY Change	-42.73%	-24.82%	109.8%	325.84%	-3.83%	13.99%	-3.13%	-16.12%	75.7%	-6.1%	186.73%	-26.32%	3.1%	84.29%	32.08%	35.9%	18.18%	-5.71%	133.33%
Long-Term Debt	$161.9M	$115.4M	$104.4M	$95.77M	$80.91M	$40.07M	$54.10M	$61.54M	$76.57M	$66.04M	$64.90M	$5.100M	$5.300M	$5.500M	$5.400M	$3.900M	$3.100M	$2.900M	$2.700M	$0.00
YoY Change	40.27%	10.51%	9.03%	18.36%	101.92%	-25.93%	-12.1%	-19.62%	15.95%	1.75%	1172.55%	-3.77%	-3.64%	1.85%	38.46%	25.81%	6.9%	7.41%
Other Long-Term Liabilities	$7.456M	$8.071M	$172.1M	$99.69M	$7.361M	$3.706M	$4.838M	$6.331M	$7.809M	$10.65M	$17.30M	$12.60M	$14.00M	$16.70M	$11.10M	$4.800M	$3.500M	$4.100M	$3.600M	$2.400M
YoY Change	-7.62%	-95.31%	72.62%	1254.34%	98.62%	-23.4%	-23.58%	-18.93%	-26.68%	-38.44%	37.3%	-10.0%	-16.17%	50.45%	131.25%	37.14%	-14.63%	13.89%	50.0%
Total Long-Term Liabilities	$169.3M	$123.5M	$276.5M	$195.5M	$88.27M	$43.78M	$58.94M	$67.88M	$84.38M	$76.69M	$82.20M	$17.70M	$19.30M	$22.20M	$16.50M	$8.700M	$6.600M	$7.000M	$6.300M	$2.400M
YoY Change	37.14%	-55.35%	41.46%	121.43%	101.64%	-25.72%	-13.17%	-19.56%	10.03%	-6.71%	364.41%	-8.29%	-13.06%	34.55%	89.66%	31.82%	-5.71%	11.11%	162.5%
Total Liabilities	$331.8M	$401.5M	$646.8M	$371.7M	$129.6M	$86.72M	$96.67M	$106.8M	$130.9M	$103.1M	$110.3M	$27.50M	$32.60M	$35.20M	$23.40M	$14.00M	$10.60M	$10.30M	$9.800M	$3.900M
YoY Change	-17.37%	-37.92%	73.98%	186.9%	49.41%	-10.3%	-9.51%	-18.36%	26.95%	-6.55%	301.09%	-15.64%	-7.39%	50.43%	67.14%	32.08%	2.91%	5.1%	151.28%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $428.58 Million

About Valneva SE

Valneva SE is a specialty vaccine company, which focuses on the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 684 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Industry: Biological Products, (No Diagnostic Substances) Peers: